Safety and Efficacy of Evolocumab in patients with acute coronary syndrome underwent to Coronary Artery Bypass Graft: a comparative retrospective analysis
Anno:
2024
Background. In-hospital reduction of low-density lipoprotein cholesterol (LDL-C) levels following the acute coronary syndrome (ACS) is recommended in the current clinical guidelines. However, the efficacy of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors (Evolocumab) in these patients undergoing surgical coronary revascularization has not been demonstrated. Methods. From January 2022…